[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430695":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":37,"studyPopulation":30,"armGroups":38,"interventions":46,"overallOfficials":60,"centralContacts":67,"locations":76,"responsibleParty":165,"collaborators":168,"id":172,"slug":30,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":173,"sex":179,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":30,"studyType":185,"phases":186,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":92,"whyStopped":30,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"Tongji Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Objective Response Rate (ORR)","Objective Response Rate using RECIST 1.1 criteria, Proportion of patients with CR and PR","about 24 month",[14,17,20,23,27],{"measure":15,"description":16,"timeFrame":12},"Progression-free Survival","Time from the date of first dose to first observation of progression (RECIST1.1) or date of death (from any cause)",{"measure":18,"description":19,"timeFrame":12},"Overall Survival","Time from the date of first dose to death from any cause",{"measure":21,"description":22,"timeFrame":12},"Duration of response","Time from the date of the first documented response (CR or PR) to the earliest date of disease progression (RECIST 1.1), or death due to any cause.",{"measure":24,"description":25,"timeFrame":26},"incidence, type and severity of adverse events","Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0","From time of informed consent through treatment period and up to 30 days post last dose of study treatment (about 24 months)",{"measure":28,"description":29,"timeFrame":12},"Disease control rate","Disease control rate using RECIST 1.1 criteria, Proportion of patients with CR, PR and SD",null,{"allocation":32,"interventionModel":33,"interventionModelDescription":30,"primaryPurpose":34,"observationalModel":30,"timePerspective":30,"maskingInfo":35},"NA","SINGLE_GROUP","TREATMENT",{"masking":36,"maskingDescription":30,"whoMasked":30},"NONE","This trial enrolled patients with advanced or metastatic pulmonary sarcomatoid carcinoma. Patients will receive camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day. The primary endpoint is objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response, and safety.",[39],{"label":40,"type":41,"description":42,"interventionNames":43},"Camrelizumab + Famitinib","EXPERIMENTAL","Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.",[44,45],"Drug: Camrelizumab","Drug: Famitinib",[47,54],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"DRUG","Camrelizumab","Patients received camrelizumab 200 mg every 3 weeks",[40],[53],"SHR-1210",{"type":48,"name":55,"description":56,"armGroupLabels":57,"otherNames":58},"Famitinib","Patients received Famitinib 20 mg once per day",[40],[59],"SHR-1020",[61,64],{"name":62,"affiliation":5,"role":63},"Qian Chu","PRINCIPAL_INVESTIGATOR",{"name":65,"affiliation":66,"role":63},"Lin Wu","Hunan Cancer Hospital",[68,73],{"name":62,"role":69,"phone":70,"phoneExt":71,"email":72},"CONTACT","13212760751","+86","qianchu@163.com",{"name":65,"role":69,"phone":74,"phoneExt":71,"email":75},"13170419973","wulin-calf@vip.163.com",[77,90,104,113,125,134,143,156],{"facility":78,"status":79,"city":80,"state":81,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":30},"The first Affiliated Hospital of Xiamen University","ACTIVE_NOT_RECRUITING","Xiamen","Fujian","China","CN",{"type":85,"coordinates":86},"Point",[87,88],118.08187,24.47979,{"lat":88,"lon":87},{"facility":91,"status":92,"city":93,"state":94,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University","RECRUITING","Zhengzhou","Henan",{"type":85,"coordinates":96},[97,98],113.64861,34.75778,{"lat":98,"lon":97},[101],{"name":102,"role":69,"phone":30,"phoneExt":30,"email":103},"Huijuan Wang, Ph.D","18638561588@163.com",{"facility":105,"status":92,"city":93,"state":94,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"Henan Provincial People's Hospital",{"type":85,"coordinates":107},[97,98],{"lat":98,"lon":97},[110],{"name":111,"role":69,"phone":30,"phoneExt":30,"email":112},"Cangshun Dong, Ph.D","cangshundong@163.com",{"facility":62,"status":92,"city":114,"state":115,"zip":116,"country":82,"countryCode":83,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Wuhan","Hubei","430000",{"type":85,"coordinates":118},[119,120],114.26667,30.58333,{"lat":120,"lon":119},[123],{"name":124,"role":69,"phone":70,"phoneExt":71,"email":72},"Qian Chu, Ph.D",{"facility":126,"status":92,"city":114,"state":115,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":127,"geoPoint":129,"contacts":130},"Hubei Cancer Hospital",{"type":85,"coordinates":128},[119,120],{"lat":120,"lon":119},[131],{"name":132,"role":69,"phone":30,"phoneExt":30,"email":133},"Bin Yang","245463239@qq.com",{"facility":135,"status":92,"city":114,"state":115,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":136,"geoPoint":138,"contacts":139},"Renmin Hospital of Wuhan University Hubei General Hospital",{"type":85,"coordinates":137},[119,120],{"lat":120,"lon":119},[140],{"name":141,"role":69,"phone":30,"phoneExt":30,"email":142},"Qibin Song, Ph.D","qibinsong@whu.edu.cn",{"facility":144,"status":92,"city":145,"state":146,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"The Second Xiangya Hospital of Central South University","Changsha","Hunan",{"type":85,"coordinates":148},[149,150],112.97087,28.19874,{"lat":150,"lon":149},[153],{"name":154,"role":69,"phone":30,"phoneExt":30,"email":155},"Xianling Liu, Ph.D","liuxianling@csu.edu.cn",{"facility":157,"status":79,"city":158,"state":159,"zip":30,"country":82,"countryCode":83,"cosmosGeoPoint":160,"geoPoint":164,"contacts":30},"The First Affiliated Hospital of Shandong First Medical University","Jinan","Shandong",{"type":85,"coordinates":161},[162,163],116.99722,36.66833,{"lat":163,"lon":162},{"type":166,"investigatorFullName":62,"investigatorTitle":167,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Professor",[169],{"name":170,"class":171},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY","100430695",false,"NCT04888429","Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma","Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma：A Multi-center, Single-arm Study","CAPSTONE","Inclusion Criteria:\n\n* Patients with histologically stage IIIB, IIIC, IV Pulmonary Sarcomatoid Carcinoma according to WHO criteria or diagnosed with non-small cell lung cancer with sarcomatoid carcinoma component (sarcomatoid component tumour cells can be spindle cells, and\u002For giant cells and\u002For heterogenous sarcomatous differentiation including rhabdomyosarcoma, chondrosarcoma, etc.) ；\n* Has no prior systemic therapy; (chemotherapy and\u002For radiotherapy is allowed as part of neoadjuvant\u002Fadjuvant therapy. Patients who have had recurrence or metastasis for more than 6 months from the end of neoadjuvant\u002Fadjuvant treatment would be enrolled ) ；\n* Patients must have at least one measurable lesion according to RECIST 1.1 ；\n* ECOG score 0-1 ；\n* Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing) ；\n* Life expectancy more than 3 months;\n* Has adequate organ function；\n\nExclusion Criteria:\n\n* Imaging (CT or MRI) showed tumor invasion of major vessels. hemoptysis ≥ 2.5 mL within 1 month before the first dose;\n* Patients with EGFR-sensitive mutation (19Exondel\u002FL858R), ALK, ROS1 gene rearrangement or fusion, BRAFV600E mutation, MET gene exon 14 skipping mutation;\n* Patients with active bleeding or bleeding tendency ；\n* With hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure ≤ 140 mmHg\u002Fdiastolic blood pressure ≤ 90 mmHg)；\n* Urine protein ≥ (+ +), and 24-hour urine protein ≥ 1.0g;\n* Presence of thrombotic disorder requiring anticoagulant therapy with warfarin or heparin, or requiring antiplatelet therapy (aspirin ≥ 300 mg\u002Fday or clopidogrel ≥ 75 mg\u002Fday) ；\n* Has multiple factors affecting the absorption of oral drugs, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction\n* Has active central nervous system (CNS) metastases confirmed by CT or MRI\n* Subjects diagnosed immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy of non-related tumor within 7 days before the first dose; allowed physiological dose of glucocorticoid (≤10 mg\u002Fday Prednisone or equivalent);\n* Has active hepatitis B ;\n* Has severe infections within 4 weeks of the first dose of study treatment ;\n* Women who are pregnant or lactating ;\n* With grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (QTc interval ≥ 450 ms for males and QTc interval ≥ 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with left ventricular ejection fraction (LVEF) less than 50% according to NYHA criteria;\n* Has known history of Human Immunodeficiency Virus (HIV)；\n* Has known allergy to Camrelizumab, or famitinib or any of accessories ;","ALL","18 Years","75 Years",{"count":183,"type":184},28,"ESTIMATED","INTERVENTIONAL",[187],"PHASE2","This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.",[190],"Sarcomatoid Carcinoma of Lung",[190,49,55],"2024-09-26",{"date":194,"type":195},"2024-10-01","ACTUAL",{"date":197,"type":195},"2021-07-19",{"date":199,"type":184},"2025-06-30",{"name":62,"class":6},8]